Neurofibroma
MONDO:0016755An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.
Also known as: neurofibroma, neurofibroma (WHO grade I), neurofibroma, benign, NFIB
1516 clinical trials for this condition and its sub-types, 17 tagged with Neurofibroma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neurofibroma
-
Neurofibrosarcoma 33 trials
-
Plexiform neurofibroma 29 trials
-
Atypical neurofibroma 4 trials
-
Pacinian tumor 0 trials
-
Cellular neurofibroma 0 trials
-
Epithelioid neurofibroma 0 trials
-
Mediastinum neurofibroma 0 trials
-
Neurofibroma of gallbladder 0 trials
-
Neurofibroma of spinal cord 0 trials
-
Neurofibroma of the esophagus 0 trials
-
Neurofibroma of the heart 0 trials
-
Could a cold sore virus shrink NF1 skin tumors?
Disease control Recruiting nowThis early study tests whether a drug called IMLYGIC, made from a modified herpes virus, can be safely injected into painful or disfiguring skin tumors in adults with NF1. Ten participants will receive up to 8 injections over 4 months. The goal is to see if the treatment is toler…
Phase 1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise for NF1 skin tumors in early trial
Disease control Recruiting nowThis study tests a drug called mirdametinib in adults with neurofibromatosis type 1 (NF1) who have skin tumors called cutaneous neurofibromas. The goal is to find a safe dose and see if the drug can shrink these tumors. About 24 people will take the drug daily or on a three-week-…
Phase 1/2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Pen-Like device could help surgeons detect cancer in real time
Diagnosis Recruiting nowThis study tests whether a handheld device called the MasSpec Pen can tell the difference between cancerous MPNST, benign neurofibromas, and normal tissue during surgery. About 60 people with MPNST or neurofibroma will take part. The goal is to see if the device is safe and accur…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New MRI scan could help surgeons tackle tricky spinal tumors
Diagnosis Recruiting nowThis study is testing whether a special MRI technique called magnetic resonance elastography (MRE) can measure how stiff a spinal cord tumor is and how strongly it sticks to surrounding tissue before surgery. Knowing this could help surgeons choose the best approach and make oper…
Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
New study hopes to spot cancer early in NF1 patients
Knowledge-focused Recruiting nowThis study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
New questionnaires could help NF1 patients voice appearance concerns
Knowledge-focused Recruiting nowThis study is developing questionnaires to measure how visible tumors in neurofibromatosis type 1 (NF1) affect patients' appearance concerns. About 110 participants, including children, adults, and caregivers, will complete surveys and join focus groups or interviews to give feed…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC